medRxiv preprint doi: https://doi.org/10.1101/2024.12.13.24318201; this version posted December 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The DiaGame Study: Multimodal Data Collection in Free-Living 1

Conditions Using Consumer-Level Wearable Devices and Apps in 2

3

People with Diabetes

- 4 Ryan de Vries^{1*†}, Edouard F.H. Reinders^{2,5*}, Danilo Ferreira de Carvalho³, Elma
- 5 M.W.L. Cruts – Van de Meulengraaf², Pieter M.E. van Gorp⁴, Pleun C.M. Wouters -
- van Poppel², Uzay Kaymak³, Peter A.J. Hilbers¹, Natal A.W. van Riel^{1‡}, Harm R. 6
- 7 Haak^{2,5‡}
- 8 Shared first-author
- 9 [‡]Equal contributions
- 10 [†]Corresponding author: <u>r.d.vries@tue.nl</u>
- 11 ¹Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
- 12 ²Máxima MC, Department of Internal Medicine, Eindhoven/Veldhoven, The Netherlands
- 13 ³Jheronimus Academy of Data Science, Eindhoven University of Technology, 's-Hertogenbosch, The Netherlands
- 14 15 ⁴Department of Industrial Engineering & Innovation Sciences, Eindhoven University of Technology, Eindhoven, The Netherlands
- 16 17 ⁵Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, The Netherlands
- 18

Abstract

- 19 The everlasting interest in precision medicine has instigated a need for patient-specific 20 multidimensional data collection. By leveraging consumer-level wearable devices and 21 applications we can support this need by collecting multimodal data in uncontrolled free-22 living conditions. We used a continuous glucose monitor, a smartwatch with in-house 23 developed application, and a smartphone application over a period of 14 days to collect data 24 from 60 participants with diabetes. Data were collected on 77,683 CGM measurements, 25 4,073 moods, 3,517 meals, 1,394 insulin injections, and 1,364 bouts of physical activity. 26 Participants were able to effectively use the devices and applications, with 45 participants 27 reporting data on all modalities and all participants reporting data on at least two modalities 28 (in addition to the data collected from the smartwatch's internal sensors). These findings 29 highlight the efficiency and effectiveness of consumer-level wearable devices to collect data 30 from the comfort of the people's homes. Thereby, facilitating the need for a cost-effective 31 and scalable approach for precision monitoring to the public.
- 32 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33

Introduction

34 The emergence of precision or personalized medicine, which seeks to improve 35 diagnosis, prediction, prevention, and treatment by focusing on the individual rather 36 than on groups of people, has instigated a need for patient-specific multidimensional 37 data to evaluate an individual's health, wellbeing, and environment. Diabetes 38 mellitus, a chronic endocrine disease characterized by chronically elevated blood 39 glucose levels, is one example of a disease for which precision medicine approaches 40 can prove to be beneficial, due to the recognized heterogeneity in its etiology, clinical 41 presentation, and pathogenesis¹. The resulting need for patient-specific 42 multidimensional data collection (precision monitoring) in people with diabetes has 43 been highlighted in the latest American Diabetes Association (ADA) and European 44 Association for the Study of Diabetes (EASD) consensus, along with recent 45 publications, that advocated for precision monitoring methods as the next crucial 46 step towards precision medicine for diabetes^{1,2}. Precision medicine in the field of 47 diabetes research focuses on elucidating pathophysiological processes (molecular 48 and environmental), and consequently the heterogeneity in glycemic dynamics, that 49 underly the disease. Although the primary cause of dysregulated glycemic dynamics 50 concerns defects in at least one physiological pathway, multiple coherent factors 51 including self-regulated behavior (e.g., dietary intake and physical activity) and 52 health (e.g., medication and psychological status) also influence glycemic dynamics. 53 Furthermore, lifestyle, defined by the long-term combination of these variables. impacts the risk for future complications^{3–7}. 54

55 To capture glycemic variations, gain insight into the underlying glycemic effects of 56 lifestyle, and ultimately monitor disease progression, all at an individual level, the 57 availability of data is imperative. Although data measured in clinical and research

58 settings are well controlled, detailed data collection over weeks or months of time is 59 unfeasible from these settings and difficult to scale to large cohorts. Consequently, a 60 transition must be made towards data measured in the comfort of people's homes 61 and throughout their daily lives. Furthermore, data from free-living conditions are 62 representative of self-regulated behavior and habits, while measurements in 63 controlled clinical settings are not, and these data offer the opportunity to capture the 64 day-to-day glycemic variability typical for diabetes. The shift from clinical settings 65 towards free-living conditions, to collect data for healthcare and research purposes. 66 is enabled by the advent and enhancement of wearable devices. The continuous 67 glucose monitor (CGM) has already provided tremendous insight into glycemic 68 control for clinicians and people with diabetes⁸. Furthermore, smartphones and 69 smartwatches have been shown to be promising for the monitoring of lifestyle 70 variables (i.e., assessment of physical activity, diet, and psychological stress)^{9,10}.

71 The use of wearable devices in diabetic populations for data collection in free-living conditions has, except for a few studies, been mostly limited to the effects on blood 72 73 glucose levels of physical activity, diet, or psychological stress alone. The limited 74 number of studies that simultaneously collected data on a broader range of variables 75 associated with glycemic variability, have almost all been conducted with people with 76 type 1 diabetes. Marling & Bunescu (2020) collected data in 12 participants with type 77 1 diabetes for eight weeks on blood glucose levels (CGM), dietary intake, physical 78 activity, usage of insulin analogues and other antidiabetic medication, and 79 psychological status in free-living conditions¹¹. Other studies such as the D1NAMO 80 project (nine participants with type 1 diabetes, four-day study period) have collected 81 data on electrocardiograms, breathing, accelerometers, CGMs, and annotated food 82 pictures¹². The ShanghaiT1DM & ShanghaiT2DM datasets (12 participants with type

83 1 diabetes and 100 participants with type 2 diabetes, study period up to 14 days) included dietary intake, insulin injections, and CGM data¹³. Nevertheless, while these 84 85 studies collected multimodal data in free-living conditions in people with type 1 86 diabetes, similar studies including people with type 2 diabetes are rare. Zahedani et 87 al. (2023) used a CGM, a proprietary app for food logging, and heart rate data from a 88 smartwatch to demonstrate that app-based lifestyle recommendations can improve 89 eating habits, markers of glycemic variability, and weight in a predominantly healthy 90 and prediabetic cohort (N = 1,066, including 94 subjects with non-insulin-treated type 91 2 diabetes)¹⁴. Similarly, Pai et al. (2024) collected data from a CGM, app-based food 92 logging, and accelerometer-derived step count to stratify postprandial peaks into 93 normal and elevated categories and highlighted the relationship between post-meal 94 steps and a reduced postprandial glucose response in Hispanic/Latino adults (N = 95 36, including 14 subjects with non-insulin-treated type 2 diabetes)¹⁵.

96 Data collection in free-living conditions can be burdensome for the participants and 97 researchers, especially when using analog data collection methods (i.e., paper 98 logbooks and questionnaires). The data collection process often requires data 99 digitization, structuring, and manual preprocessing. Some studies also relied on 100 participants or experts to acquire information on dietary macronutrient composition. 101 Dubosson, et al. (2018) used picture-based food annotation by a dietitian, while 102 Marling & Bunescu (2020) relied on patient estimates to infer carbohydrate intake. 103 By integrating multiple wearable devices, and applications, some of the burdens of 104 data collection in free-living conditions can be alleviated. The use of wearable 105 devices negates the need for data inference and digitization. Moreover, the use of 106 specifically consumer-level wearable devices, rather than research-dedicated 107 devices, offers a cost-effective, scalable, and readily available method of collecting

108 data due to the widespread ownership of smartphones and the increasing popularity 109 of smartwatches and fitness trackers. The consumer-level wearable devices, used in 110 this study, included a CGM for continuous blood glucose measurements, a 111 smartphone application to collect patient-reported dietary intake and physical activity. 112 and a smartwatch to measure heart rate, acceleration, and step counts. The 113 smartwatch is supplemented with an in-house developed application (publicly 114 available) to allow participants to self-report mood and insulin usage. This application 115 also incorporates a nudging mechanism, using vibrations and visual prompts on the 116 screen, to encourage participants to report information as requested by the research 117 team. The use of consumer-level wearable devices ultimately enables large-scale, 118 patient-centered, and researcher-independent personalized data collection. 119 This article describes how commercially available consumer-level wearable devices 120 and apps were used to collect data in free-living conditions in people with diabetes, 121 predominantly type 2 diabetes. Subsequently, we assessed the feasibility of using 122 wearable devices in this study population, which is typically older, and analyzed the 123 effectiveness of our approach in terms of both the quantity and quality of the data 124 collected. These data included measurements of blood glucose levels, detailed 125 dietary intake, physical activity, insulin use, and mood over a 14-day period, 126 supplemented with demographics and clinical measurements. Ultimately, we aim to 127 showcase the ease and extent to which multimodal data can be collected in free-128 living conditions using consumer-level wearable devices and applications in a 129 diabetic population (predominantly type 2).

130	Results
131	Participant Characteristics
132	Upon study completion, 59 participants (35 males and 24 females) were included
133	(excluding one dropout due to multiple CGM malfunctions). For one participant CGM
134	data of her own prescribed CGM was voluntarily provided due to device malfunction.
135	51 participants were diagnosed with type 2 diabetes and eight with type 1 diabetes,
136	with respective mean ages of 69·1 years (SD 7·1) and 54·6 years (SD 16·9), mean
137	BMIs of 30·1 kg/m ² (SD 4·9) and 25·4 kg/m ² (SD 3·3), mean diabetes durations of
138	20.5 years (SD 7.3) and 26.6 years (SD 13.4), mean HbA1c's of 61.5 mmol/mol (SD
139	11.7) and 63.4 mmol/mol (SD 15.0), and mean time in ranges (3.9-10.0 mmol/L)
140	during the study of 66.8% (SD 22.7) and 62.7% (SD 21.6). For a complete overview
141	of participant characteristics (e.g., insulin and medications use, anthropometric
142	measurements, and fasting blood values), stratified by diabetes type, see Table 1.
143	Data Quantity
144	The set of wearable devices provided a large extent of multimodal data (Fig. 1
145	showcases an example of four days of collected data). Data in Fig. 1 includes sensor
146	measurements of interstitial glucose concentrations and heart rate as well as self-
147	reported mood, insulin analogue injections, dietary intake (only carbohydrate content
148	is shown here), and physical activity. The data not only provided insight into the day-
149	to-day glucose variability at an individual level, but glycemic variations can also be
150	associated with reported self-regulated behavior. In this example, rises in blood
151	glucose levels were associated with high-carbohydrate meals and drops with
152	adequate preprandial insulin administration or periods of reported physical activity
153	with an elevated heart rate. In total, the dataset includes 77,683 CGM
154	measurements, 4,073 self-reported moods, 3,517 meals, 1,394 insulin injections,

155 and 1,364 bouts of physical activity. Excluding days of study visits, interstitial glucose 156 levels were measured (every 15 minutes) in 97.5% of measurement instances. A 157 daily energy intake of at least 1,000 kcal/day was reported on 80.6% of study days 158 (excluding a single participant who was known to have started a crash-diet prior to 159 study participation), while at least 1,000 steps a day were recorded on 93.0% of 160 study days (excluding one wheelchair-bound participant). 96.6% of participants self-161 reported their mood, and 84.1% of insulin-dependent participants (n=44) reported 162 insulin doses. 84.5% of participants had self-reported physical activity, 45 163 participants (76.3%) managed to self-report data of every modality (including insulin 164 doses when prescribed). Further analysis demonstrated participants were 165 consistently engaged (i.e. they reported data) with the applications and smartwatch 166 during the study period, only with a slight decrease in physical activity reporting after 167 the second and third study days (Supplemental Fig. S3). The number of days 168 participants reported data on each modality varied between participants (shown in 169 Fig. 2). Excluding visit days, dietary intake had been reported for 11 to 13 days by all 170 participants (67.8% with a daily energy intake greater than 1,000 kcal/day). The 171 number of days with bouts of physical activity, which had a qualitatively similar 172 distribution to the number of days with at least 3,000 steps, ranged from between 173 nine and 13 days (total of 54.2%) to only one or no day (total of 27.1%). Mood was 174 self-reported anywhere between zero (3.4%) and 13 (22.0%) days, with more than 175 half (50.8%) of the participants reporting mood for at least ten days. 70.5% of 176 insulin-dependent participants reported insulin usage for 11 to 13 days, while seven 177 out of 44 (15.9%) of these participants (only one of these seven used rapid-acting 178 insulin) did not report insulin usage at all.

179

Data Quality

180 Evaluation of the quality of the patient-reported data suggested mixed results, as 181 data was consistently reported but not always to the extent that it matched our 182 expectations of a complete day of lifestyle events. A comparison of reported dietary 183 intake and daily insulin doses to recommended guidelines and health records 184 demonstrated discrepancies for a subset of participants. Firstly, the reported daily 185 energy intake (shown in Fig. 3, with participants ordered by age), varied considerably 186 between participants from 55.2 kcal/day to 4,766 kcal/day. The mean energy intake 187 (excluding outliers below 1,000 kcal/day) was 1,796 kcal/day (SD 563 kcal/day) for 188 men (dashed blue line) and 1,484 kcal/day (SD 356 kcal/day) for women (dashed 189 green line). For reference, dietary reference values recommend 1,860 and 2,290 190 kcal/day for, respectively, moderately active females and males between the ages of 191 60 and 69 years¹⁶. Thus, the reported energy intake was lower than these reference 192 values. A complete breakdown of macronutrient intake (carbohydrates, sugars, 193 saturated and unsaturated fat, protein, fiber, and salt) is provided in Supplemental 194 Fig. S4. Additionally, mean reported daily energy intake was not correlated with year 195 of birth (Spearman's $\rho = -0.19$, p = 0.15).

196 Secondly, Bland-Altman plots comparing daily (accumulated) reported insulin doses 197 with prescriptions from health records, stratified by rapid and (ultra) long-acting 198 insulin analogues (Supplemental Fig. S5 and S6), showed an overall mixed 199 agreement between reported and prescribed values. The median bias of respectively 200 rapid- and long-acting analogue doses were both 0 IU/day. The relative difference 201 between reported and prescribed daily dose was between -15% and 15% for 50.2% 202 of study days for short-acting insulins (this range was defined to allow some daily 203 variability, typical for short-acting insulin treatment). There was no difference

between reported and prescribed dose on 55.5% of study days for long-acting
insulins. Otherwise, daily insulin doses were mostly underreported compared to
prescribed doses (respectively 31.6% and 31.0%). Note for example the distinct
declining line of points for long-acting insulins that correspond to days without
reported doses. Nonetheless, the deviations in the reported daily doses could be
attributed to a subset of individuals (Supplemental Fig. S7 and S8).

210 Ecological momentary assessment of mood with the nudging mechanism using the 211 smartwatch provided a method to repeatedly gain insight into psychological status 212 within the natural flow of life. Of the five mood categories, participants primarily 213 reported being happy (13.5%) or relaxed (78.9%) throughout the day (Fig. 4), while 214 stressed (5.4%), sad (1.2%), and angry (1.0%) were reported less frequently. 215 Moreover, mood was reported most frequently shortly after participants were 216 nudged, evident by a considerably higher number of reports during the hours of the 217 day including 08:00, 12:00, 18:00, and 20:00. Differences in the number of reports at 218 these four times can be attributed to differences in wearing percentage and response 219 percentage. Firstly, the wearing percentage was lower at 52.7% (95% CI, 49.1% -220 56.3%) in the morning compared to 94.0% (95% CI, 92.1% – 95.6%), 95.6% (95% 221 CI, 93.9% – 96.9%), and 96.1% (95% CI, 94.5% – 97.3%) at 12:00, 18:00, and 222 20:00, respectively. Secondly, the nudging response percentage was considerably 223 lower at noon with 33.0% (95% CI, 29.6% – 36.6%) compared to 18:00 and 20:00 224 with respectively 41.5% (95% CI, 37.9% - 45.1%) and 42.1% (95% CI, 38.5% -225 45.7%), while the response percentage at 08:00 was 35.4% (95% CI, 30.7% – 226 40.3%). Thus, the nudging mechanism was most effective in the evening times. 227 These wearing and response percentages, overall and stratified by nudge time, did 228 not decrease throughout the study period and were unaffected by the check-up call

around study day five (Supplemental Fig. S9 and S10). Nevertheless, similar to the reported dietary intake and insulin doses, the response percentages varied considerably among participants, ranging from 0% to 96% during the observational period (Supplemental Fig. S11). However, the percentages of responses to the nudging were not correlated with the number of moods reported outside of the nudging times (Spearman's $\rho = -0.08$, p = 0.53).

235

Discussion

236 By leveraging consumer-level wearable devices, supplemented with applications and 237 a nudging mechanism, we aimed to efficiently collect multimodal personal data in 238 free-living conditions on glycemic dynamics and an extensive set of associated 239 variables (dietary intake, insulin administration, physical activity, and mood). 240 Furthermore, the effectiveness and feasibility of using multiple wearable devices 241 (CGM, smartphone, and smartwatch) with corresponding applications was assessed 242 for data collection in a study population typical of type 2 diabetes (relatively old age 243 and various comorbidities).

244 Our study showcased the opportunity to harness wearable devices as a feasible 245 method of multimodal longitudinal data collection under free-living conditions in 246 individuals. These devices required minimal calibration steps, could be operated by 247 participants following a short instruction session, and no major problems were 248 identified by the research team (except for two CGM sensor failures) or reported by participants. Moreover, the interaction of the participants with the applications was 249 250 effective, reflected by the high percentage of participants providing self-reported 251 information. Additionally, the use of a blinded CGM negated the need to scan every 252 eight hours, potentially leading to loss of data and avoided influencing the 253 participant's decision-making. The commercial availability of these consumer-level

devices and public access to the applications allows for time-effectiveness and easy
scalability to large cohorts. These devices, thereby, provide the means to obtain
continuous insight into lifestyle and personalized glycemic dynamics to the public
and optionally their healthcare providers.

258 The combination of a CGM, a smartwatch, and a smartphone application provided 259 insight into the daily life of an individual, from the comfort of their home, of which 260 limited information was otherwise available. However, data collected under free-261 living conditions is usually not a comprehensive description of all lifestyle events. 262 Evaluation of data guality indeed indicated that participant-reported data did not 263 always compare to expectations, with heterogeneity in the magnitude of these 264 differences between participants. Firstly, the energy intake reported through the 265 smartphone application (Fig. 2) was, on average, lower than expected (around 450 266 kcal/day lower) considering the European guidelines for moderately active women 267 and men between the ages of 60 and 69 years¹⁶. Nonetheless, the mean reported 268 energy intake was comparable to another study using the same smartphone 269 application in a younger non-diabetic population (1,830 kcal/day, SD 485 kcal/day, 270 n=100), which concluded that the application provided comparable results to 24-hour 271 recalls. Dubosson et al., whom relied on picture-based food annotation by a dietitian, 272 reported similar daily energy intakes (1,672 kcal/day, SD 1,038 kcal/day, n=8)^{12,17}. 273 Additionally, mean daily carbohydrate intake was similar to participant-reported 274 values in people with type 1 diabetes¹¹. Therefore, even though the energy intake 275 may deliberately be reduced or underreported by participants during a study focused 276 on lifestyle observation, partially accounting for the discrepancy, accurate dietary 277 intake assessment in free-living conditions remains challenging. Nonetheless, all 278 participants had reported dietary intake for at least 11 days. The participant's age did

not appear to be a limiting factor in reporting dietary intake using a smartphone
application, even with a generally older cohort typical for type 2 diabetes.

281 Secondly, the smartwatch offered an easily accessible means for insulin usage 282 registration, which needed no connection to the internet or a smartphone and was 283 always at hand for participants. These reported insulin doses were accurate on a 284 majority of the study days, when they could be compared to prescribed insulin treatments. These comparisons demonstrated that only five out of 36 long-acting 285 286 insulin users, and no short-acting insulin users, failed to report at least one day for 287 which the accumulated daily insulin dosages were comparable to their health 288 records. However, the accumulated daily insulin dosages derived from insulin reports 289 were frequently lower than prescribed (especially evident when one dose a day was 290 prescribed, and none were reported). It is unclear why insulin administration was 291 underreported. While daily dose adjustments are inherently part of the short-acting 292 insulin treatment, the quality of reported data on insulin use may be affected by the 293 otherwise repeated nature of daily insulin dosing leading to a lack of urgency to 294 consistently report these events. It has already been shown that data on insulin 295 dosing can be effectively collected from insulin pumps¹⁸, which are predominantly 296 used by people with type 1 diabetes, whereas the recent development of smart 297 insulin pens could potentially alleviate the burden of insulin dose registration 298 altogether.

Thirdly, ecological momentary assessment of mood using the smartwatch,
supplemented with a nudging mechanism four times a day, appeared to be an
effective method to collect information on the perceived mood of participants.
Participant involvement was consistent throughout the study period with high
wearing percentages (except in the early morning when several participants may not

304 yet have woken up) and overall steady response percentages. Participants for whom 305 the nudging mechanism was less effective still provided ample mood reports without this nudging encouragement. In addition to providing a means to report mood and 306 307 insulin doses, the smartwatch enabled the measurement of heart rate, acceleration, 308 and step count to independently inform on physical activity (next to participant-309 reported physical activity). Lastly, the mean daily value of none of the variables 310 reported by the participants decreased considerably throughout the study period; 311 which, if this had happened, could have suggested that the data collection protocol 312 may have placed too much of a burden on the participants. Thus, while the collected 313 data may not be a complete description of all daily events, these wearable devices 314 can effectively be used to acquire multimodal data in free-living conditions. Hereby 315 answering the call for precision monitoring methods as the next step towards precision prevention, diagnostics, and prognostics ^{1,2}. 316

317 We acknowledge that the study cohort consisting of known patients does not provide 318 a complete cross-sectional overview of the diabetic population in the Netherlands. 319 Nonetheless, the study cohort is typical for a type 1 and 2 diabetes cohort, when 320 compared to other studies in terms of patient characteristics. Inclusion may be 321 biased for participants with at least some affinity for digital devices as those 322 unfamiliar or hesitant to use wearable devices may be more likely to refuse 323 participation. These latter people may need additional support to promote adequate 324 use of these wearable devices.

Multiple enhancements could further enrich the collected data through the inclusion of standardized at-home meals and meal tolerance tests¹⁹. Furthermore, the registration of medication usage can be extended from the use of solely exogenous insulin to oral medications (e.g., metformin and GLP-1 agonists). Adherence to these

329 medications was currently assumed to be consistent throughout the study period, 330 even though in practice adherence has shown to be inconsistent²⁰. Additionally, real-331 time communication between devices can enable personalized nudging 332 mechanisms, by incorporating information from all devices, for Just-In-Time Adaptive 333 Interventions²¹. Tailoring the timing, frequency, and format of the nudging to the 334 individual may improve effectiveness, while just-in-time nudging could be used to 335 promote reports on dietary intake or insulin injections when blood glucose excursions 336 are observed (currently the nudging mechanism was limited to data collection on 337 mood due to the inherent continuity of human mood, which is lacking in all other 338 variables).

339 The data collected in free-living conditions holds the potential for various clinical 340 purposes, as indicated by the growing interest and recent increase in research within 341 this field. Firstly, it offers a deeper understanding of intra-day and inter-day glycemic 342 variability at an individual level. This understanding enables healthcare providers to 343 deliver targeted and personalized care (precision medicine), which may contribute to 344 improved health outcomes (e.g., to deliver app-based personalized lifestyle 345 recommendations¹⁴). Secondly and more importantly, the collected data offers 346 valuable insights when analyzed across broader groups. It can reveal inter-individual 347 variations, facilitating the identification of distinct subgroups within the diabetes 348 population, unveiling their distinct characteristics and needs (e.g., to stratify meal 349 events for digital phenotyping¹⁵). Lastly, these data can support the development of 350 next-generation simulators and digital twins, general or personalized dynamic 351 metabolic models capable of predicting glucose levels and their modulation due to daily activities²². Such models have the potential to serve multiple purposes, from 352 353 enhancing broader group-level education by showcasing the response of blood

354 glucose levels to lifestyle decisions to *in silico* experiments with virtual patient 355 cohorts. A deeper understanding of a disease like diabetes and the various factors 356 influencing blood glucose levels can foster increased self-confidence and effective 357 self-management in people with diabetes. Given that improved self-management in 358 diabetes correlates with better health and reduced short- and long-term 359 complications, the significance of this understanding is clear²³. Furthermore, 360 diabetes self-management education and support (DSMES) currently occurs 361 predominantly through one-on-one consultations with healthcare providers. 362 However, with the escalating numbers of patients with diabetes globally, there is a 363 growing need for more scalable, sustainable, and affordable support. Electronic 364 resources and digital interventions, such as advanced simulators, predicting glucose 365 levels at a personal level, could offer a crucial addition to future healthcare. They 366 hold the potential to make healthcare more efficient and accessible while 367 simultaneously improving its quality.

368

Conclusion

369 Our study showcased the feasibility and effectiveness of consumer-level wearable 370 devices for multimodal data collection in free-living conditions, in a predominantly 371 type 2 diabetes cohort. Moreover, the protocol can be scaled to larger cohorts and 372 easily reproduced and integrated due to the commercial or free availability of the 373 devices and applications. The multimodal data that can be measured in free-living 374 conditions, by relying on wearable devices, applications, and the people themselves, 375 give us the opportunity for precision monitoring to individualize patient care by 376 accounting for intra- and inter-day heterogeneity in glycemic dynamics. Moreover, 377 the data support further research into the effects of self-regulated behavior and 378 health on glycemic dynamics and the long-term progression of the disease.

- 379 Ultimately, enabling us to provide patients with personalized approaches for diabetes380 treatment and self-management support.
- 381

STAR Methods

382 Study Design and Participants

383 Between June 2022 and June 2023, 60 participants (both type 1 and type 2 384 diabetes) were included and data were collected over a consecutive 14-day period. 385 All participants were recruited from the outpatient clinic of the Máxima Medical 386 Centre (The Netherlands). Participants were eligible for inclusion when they met the 387 following criteria: (I) diagnosis of type 2 diabetes or type 1 diabetes (body mass 388 index (BMI) < 30 kg/m² for type 1 diabetes), (II) age > 18 years, (III) possession of a 389 smartphone that runs the required application. Exclusion criteria comprised: (I) 390 pregnancy or breastfeeding, (II) ongoing treatment for malignancy, (III) scheduled 391 MRI scan during the study, and (IV) non-Dutch speaking. All individuals provided 392 written informed consent. The study was registered in the Dutch Trial Registry 393 (NL9290), approved by the Medical Research Ethics Committee Máxima MC (nr. 394 L20.102), and conducted according to the principles of the Declaration of Helsinki. 395 Participation consisted of two visits to the clinic and a telephone call. During the first 396 visit, a brief overview of the participant's medical history was registered, along with 397 medication use. Subsequently, blood pressure, resting heart rate, weight, and length 398 were measured and a blinded CGM was applied. Finally, participants received a 399 smartwatch with preinstalled study application, were instructed on how to download 400 the smartphone application, and use the devices.

401 Four to six days after the first visit participants were contacted by telephone to
402 address specific issues, identified through a remote assessment of data reported on

dietary intake and physical activity. Instructions were reiterated if necessary.
Subsequently, after 14 days, participants returned for the second visit in a fasted
state to draw blood and return all devices. The data on these devices were
subsequently pseudonymized and exported to a secure database.

407 Data Collection

408 Glucose concentrations were measured using a *FreeStyle Libre Pro iQ* sensor

409 (Abbott Diabetes Care, Illinois, USA), a blinded CGM that measured interstitial

410 glucose levels every 15 minutes, 24 hours per day, for 14 consecutive days.

411 Glycated hemoglobin (HbA1c), fasting glucose, and c-peptide concentrations were

412 measured using the standard protocol of the hospital's clinical chemical laboratory.

413 Participants received a Samsung Galaxy Watch 2 Active 44mm smartwatch during

414 visit 1, pre-installed with the developed application (built for the Tizen mobile

415 operating system). The application allowed participants to report mood and insulin

416 analogue usage and automatically recorded measurements from the internal sensors

417 (heart rate monitor, pedometer, triaxial accelerometer). First, (insulin-dependent)

418 participants were instructed to self-report the type of insulin injected (short-acting,

419 long-acting, or mixed insulin), dose, and time of injection through the dedicated

420 screen. Secondly, participants were nudged four times a day at fixed times (8 AM, 12

421 PM, 6 PM, 8 PM) through short vibrations and activation of the smartwatch

422 showcasing the dedicated mood screen. The screen provided the option of five

423 moods with matching emojis: happy, relaxed, stressed, angry, and sad. Participants

424 were instructed to respond to these nudges and to report their mood when they

425 perceived a change in their mood. Nonetheless, participants retained the autonomy

426 to report mood at any time via the application. An overview of the smartwatch427 application can be seen in Supplemental Fig. S1.

428 Dietary intake, both food and beverage consumption (excluding water, tea, and 429 coffee without any additives), and physical activity were self-reported every day 430 through the *Mijn Eetmeter* smartphone application (translates to '*My Eating Meter*') 431 on the participant's smartphone (Voedingscentrum, The Hague, The Netherlands)²⁴. 432 Reporting dietary intake required participants to enter the meal moment (breakfast, 433 lunch, dinner, and snacks in between these meal moments), meal contents, and 434 amounts of these meal contents. Options for meal contents are synchronized with 435 the Dutch Food Composition Information Portal (NVIP) from the Dutch National Institute for Public Health and the Environment²⁵. The application provides 436 437 predefined portion sizes per product (e.g., one standard serving of a product or the 438 distinction between a small, medium, or large portion with an indicated weight) next 439 to the option to report the weight of the product. Instructions were given to report 440 mealtimes in an adjacent text field that listed the different meal moments. 441 Furthermore, participants were instructed to report physical activity in the application. 442 This action consisted of selecting the type of activity from a wide range of 443 possibilities (from walking to cleaning the house), the duration of the activity, and 444 noting the starting time in a text field. For an impression of the application, see 445 Supplemental Fig. S2.

446 Data Security

Participants were provided with preset study *Mijn Eetmeter* accounts to promote data
security and privacy, aligning with the General Data Protection Regulation (GDPR).
Additionally, the smartwatch and CGM operated offline during the study period.

450 Statistical Analysis

451	95% binomial proportion confidence intervals for wearing percentage (smartwatch
452	was worn at the time of a nudge) and response percentage (responses to nudges
453	when the smartwatch was determined to be worn) were calculated using Clopper-
454	Pearson "exact" confidence intervals, unless stated otherwise. The wearing of the
455	smartwatch was determined by the presence of a valid reading of the heart rate
456	sensor within one minute of nudging, whereas the response percentage was defined
457	as the percentage of responses to a nudge, within five minutes, when the
458	smartwatch was worn according to the previous criterion.
459	
460	Acknowledgements
461	This research is part of the DiaGame project funded by NWO Data2Person
462	(628.011.027).
463	Declaration of Interests
464	H.H. was a shareholder and on the board of directors of HRH Diabetes Games B.V.
465	at the time this work was conducted. All other authors declare no conflict of interest.
466	Author Contributions
467	R.V. was responsible for conceptualization, methodology, software, validation, formal
468	analysis, investigation, resources, data curation, visualization, and writing the first
469	draft of the manuscript. E.R. was responsible for conceptualization, methodology,
470	validation, investigation, resources, and writing the first draft of the manuscript. D.C.
471	worked on conceptualization, methodology, software, validation, investigation,
472	resources, and data curation. E.C. was responsible for conceptualization,

473	meth	odology, validation, investigation, and resources. P.G., P.W., U.K, P.H, N.R.,		
474	and I	H.H. contributed to conceptualization, methodology, and reviewing of the		
475	manı	uscript. Additionally, N.R. and H.H. provided supervision and acquired funding,		
476	while	N.R. was also responsible for project administration. All authors approved the		
477	defin	itive version of the manuscript.		
478		Data Availability Statement		
479	The data used and/or analyzed in the current study are available from the			
480	corresponding author upon reasonable request.			
481				
482		References		
483	1.	Chung, W. K. et al. Precision Medicine in Diabetes: A Consensus Report from		
484		the American Diabetes Association (ADA) and the European Association for		
485		the Study of Diabetes (EASD). <i>Diabetes Care</i> 43 , 1617–1635 (2020).		
486	2.	Hermanns, N. et al. Coordination of glucose monitoring, self-care behaviour		
487		and mental health: achieving precision monitoring in diabetes. Diabetologia		
488		vol. 65 1883–1894 Preprint at https://doi.org/10.1007/s00125-022-05685-7		
489		(2022).		
490	3.	American Diabetes Association. Pharmacologic approaches to glycemic		
491		treatment: Standards of medical care in diabetes-2021. Diabetes Care 44,		
492		S111–S124 (2021).		
493	4.	Colberg, S. R. et al. Physical activity/exercise and diabetes: A position		
494		statement of the American Diabetes Association. Diabetes Care vol. 39 2065-		
495		2079 Preprint at https://doi.org/10.2337/dc16-1728 (2016).		

- 496 5. Evert, A. B. et al. Nutrition therapy for adults with diabetes or prediabetes: A
- 497 consensus report. *Diabetes Care* vol. 42 731–754 Preprint at
- 498 https://doi.org/10.2337/dci19-0014 (2019).
- 499 6. O'Hearn, M. et al. Incident type 2 diabetes attributable to suboptimal diet in
- 500 184 countries. *Nat Med* **29**, 982–995 (2023).
- 501 7. Young-Hyman, D. *et al.* Psychosocial care for people with diabetes: A position
 502 statement of the American diabetes association. *Diabetes Care* vol. 39 2126–
 503 2140 Preprint at https://doi.org/10.2337/dc16-2053 (2016).
- 8. Miller, E. M. Using continuous glucose monitoring in clinical practice. *Clinical*

505 *Diabetes* vol. 38 429–438 Preprint at https://doi.org/10.2337/cd20-0043 (2020).

- 506 9. Pendergast, F. J., Ridgers, N. D., Worsley, A. & McNaughton, S. A. Evaluation
- 507 of a smartphone food diary application using objectively measured energy
- 508 expenditure. International Journal of Behavioral Nutrition and Physical Activity

14, 1–10 (2017).

- 510 10. Rodriguez-León, C., Villalonga, C., Munoz-Torres, M., Ruiz, J. R. & Banos, O.
- 511 Mobile and wearable technology for the monitoring of diabetes-related
- 512 parameters: Systematic review. *JMIR mHealth and uHealth* vol. 9 Preprint at 513 https://doi.org/10.2196/25138 (2021).
- 514 11. Marling, C. & Bunescu, R. The OhioT1DM Dataset for Blood Glucose Level 515 Prediction: Update 2020. in *CEUR Workshop Proceedings* 71–74 (2020).
- 516 12. Dubosson, F. *et al.* The open D1NAMO dataset: A multi-modal dataset for
 517 research on non-invasive type 1 diabetes management. *Inform Med Unlocked*518 **13**, 92–100 (2018).

519 13. Zhao, Q. et al. Chinese diabetes datasets for data-driven machine learning.

- 520 *Sci Data* **10**, (2023).
- 521 14. Zahedani, A. D. *et al.* Digital health application integrating wearable data and
- 522 behavioral patterns improves metabolic health. *NPJ Digit Med* **6**, (2023).
- 523 15. Pai, A. *et al.* Multimodal digital phenotyping of diet, physical activity, and
- 524 glycemia in Hispanic/Latino adults with or at risk of type 2 diabetes. *NPJ Digit*525 *Med* 7, (2024).
- 526 16. EFSA (European Food Safety Authority). Dietary Reference Values for
- 527 nutrients. Summary report. *EFSA Supporting Publications* **14**, (2017).
- 528 17. Ocké, M., Dinnissen, C., Stafleu, A., de Vries, J. & van Rossum, C. Relative
 529 validity of MijnEetmeter: A food diary app for self-monitoring of dietary intake.
 530 *Nutrients* 13, (2021).
- 531 18. Prioleau, T., Bartolome, A., Comi, R. & Stanger, C. DiaTrend: A dataset from
 532 advanced diabetes technology to enable development of novel analytic
 533 solutions. *Sci Data* **10**, (2023).
- 534 19. Héritier, H. *et al.* Food & You: A digital cohort on personalized nutrition. *PLOS*535 *Digital Health* 2, (2023).
- 536 20. Kirkman, M. S. *et al.* Determinants of adherence to diabetes medications:
- 537 Findings from a large pharmacy claims database. *Diabetes Care* 38, 604–609
 538 (2015).
- 539 21. Spruijt-Metz, D. et al. Innovations in the Use of Interactive Technology to
- 540 Support Weight Management. *Current Obesity Reports* vol. 4 510–519
- 541 Preprint at https://doi.org/10.1007/s13679-015-0183-6 (2015).

- 542 22. Katsoulakis, E. *et al.* Digital twins for health: a scoping review. *npj Digital*
- 543 *Medicine* vol. 7 Preprint at https://doi.org/10.1038/s41746-024-01073-0 (2024).
- 544 23. Davis, J. *et al.* 2022 National Standards for Diabetes Self-Management
- 545 Education and Support. *Diabetes Care* **45**, 484–494 (2022).
- 546 24. Voedingscentrum. Mijn Eetmeter. *https://mijn.voedingscentrum.nl/nl/eetmeter/* 547 (2023).
- 548 25. Dutch National Institute for Public Health and the Environment. Nederlandse
- 549 Voedingsmiddelen Informatie Portaal. https://www.rivm.nl/nederlands-
- 550 voedingsstoffenbestand/organisatie/nederlands-
- 551 *voedingsmiddeleninformatieportaal* (2024).
- 552

	Mean ± Standard Deviation		
Demographics	Type 2 Diabetes (n = 51)	Type 1 Diabetes (n = 8)	
	General		
Male	32	3	
Female	19	5	
BMI (kg/m²)	30·1 ± 4·9	25·4 ± 3·3	
Age (years)	69·1 ± 7·1	54·6 ± 16·9	
HbA1c (mmol/mol)	61·5 ± 11·7	63·4 ± 15·0	
HbA1c (%)	7·8 ± 1·1	8·0 ± 1·4	
Systolic Blood Pressure (mmHg)	133 ± 16	128 ± 13	
Diastolic Blood Pressure (mmHg)	73 ± 8	76 ± 4	
Resting Heart rate (bpm)	75 ± 17	81 ± 12	
Diabetes Duration (years)	20·5 ± 7·3	26·6 ± 13·4	
Fasting Glucose (mmol/L)	7·8 ± 2·5*	10·7 ± 4·0	
Fasting C-Peptide (nmol/L)	0·69 ± 0·44* (1 BLOQ)	0·10 ± 0·14 (5 BLOQ)	
Time in Range During the Study (%)	66·8 ± 22·7	62·7 ± 21·6	
Daily Insulin per kg bodyweight (IU/kg/day)	0.45 ± 0.45	0.44 ± 0.20	
Insulin Analogues and Medication			
Insulin Aspart	17	7	
Insulin Lispro	2	1	
NPH Insulin	2	1	
Insulin Glargine	9	0	
Insulin Detemir	2	0	
Insulin Degludec	25	5	
Mixed Insulins	1	0	
Insulin Pump Therapy	1	2	
Metformin	41	1	
SGLT2 Inhibitors	17	0	
GLP-1 Agonist	23	0	
Sulfonylureum Derivatives	25	0	

554 555

Table 1: Participant characteristics stratified by diabetes type. *n=58 as one participant had not fasted the morning of visit 2. BLOQ: Below Limit of Quantification (0.03 nmol/L for C-peptide); these

556 557 558	values were imputed with half of the detection limit concentration to calculate the corresponding presented statistic. Time in range is defined by the percentage of times CGM values were in between 3·9 and 10·0 mmol/L.
559	
560	
561	
562	
563	
564	
565	
566	
567	
568	
569	
570	
571	

medRxiv preprint doi: https://doi.org/10.1101/2024.12.13.24318201; this version posted December 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

572

573

Figures



574 Figure 1: Example of four days of data collected from one participant.

575 Panel A: CGM measurements (in mmol/L, solid black line) and reported moods (dark green circle = happy, light green square = relaxed, light red diamond = stressed; sad and angry were not reported by this participant in this interval). Panel B: Carbohydrate content (in grams) of reported dietary intake (light red circles) and reported short-acting (dark green diamonds) and long-acting (dark green circles) insulin doses (IU). Panel C: Measured heart rate in beats per minute (solid black line) and participantreported bouts of physical activity (light green shade). Accelerometer and pedometer data were excluded from this figure for clarity. medRxiv preprint doi: https://doi.org/10.1101/2024.12.13.24318201; this version posted December 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



582

583 Figure 2: Distribution of available days of collected data per participant for various data 584 modalities.

585 Distribution of the total number of days, excluding days of study visits, with collected data per 586 participant for each of the data modalities. Panel A: Distributions of available CGM measurements 587 (including all days = light green, including days with at least 90% of CGM time points = dark green). 588 Panel B: Distributions of self-reported dietary intake (including all days = light green, including days 589 with at least 1,000 kcal reported = dark green). Panel C: Distributions of self-reported physical activity 590 (red) and days with at least 3,000 steps (green). Panel D: Distributions of self-reported mood (red) 591 and insulin injection doses (green, n = 44 since not all study participants were insulin dependent).

592



595 Figure 3: Reported daily energy intake colored by sex and sorted by year of birth (ascending 596 from left to right).

597 Boxplots of the daily energy intake (kcal/day) reported from day two (day one excluded due to the 598 variability of the times of day at inclusion) until visit 2 for each participant. Participants are colored by

599 sex (blue = male, green = female, outliers are colored red) and sorted by year of birth (ascending from

600 left to right). Mean daily energy intake per sex (including outliers) is depicted by corresponding

601 dashed lines (1,655 kcal/day for males and 1,259 kcal/day for females).

602

594

603



Figure 4: Moods reported by participants at each time of day and nudging statistics at each nudging instance.

Number of moods reported at each hour of the day (angry = dark red, happy = dark green, relaxed = *light green, sad = dark blue, stressed = light red). Underneath the figure, the wearing percentage at* each nudge time (08:00, 12:00, 18:00, and 20:00) and corresponding response percentage to the

- nudges are given with 95% confidence intervals.